Provided is a method of preparing pregabalin and its important intermediate lactam compound. This method does not use hydrogen or high pressure equipment. By a convenient process, high purity of product can be obtained from selecting the proper catalyst and reducing agent with normal equipments. This method is convenient, safe and is of high yield, which is suitable for industry manufacture.

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a composition comprising milnacipran and a second active compound to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering milnacipran combined with pregabalin to a patient with FMS.

A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

FIELD: medicine pharmaceutics.SUBSTANCE: given invention refers to a sustained-release tapentadol composition also containing a second active agent wherein the above second active agent is specified in tramadol pregabalin gabapentyl or pharmaceutically acceptable salts thereof. The given composition may be used to prepare a therapeutic agent for pain management. Besides the present invention refers to a method of managing pain and conditions related to pain by administering the given composition...

The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release r...